Table 1.
Clinical patient characteristics
| Age (years) | Median 69, IQR 64—73 | |
| PSA at RP (ng/ml) | Median 8.1, IQR 5.6—12.6 | |
| pT-stage RP | T2 | 126 (42.4%) |
| T3 | 170 (57.2%) | |
| T4 | 1 (0.3%) | |
| ISUP grade | 1 | 11 (3.7%) |
| 2 | 151 (50.8%) | |
| 3 | 99 (33.3%) | |
| 4 | 9 (3.0%) | |
| 5 | 27 (9.1%) | |
| Resection margin | R0 | 258 (86.9%) |
| R1 | 39 (13.1%) | |
| pN-stage RP | N0 | 224 (75.4%) |
| N1 | 50 (16.8%) | |
| No LN dissected | 23 (7.7%) | |
| RP to PET (months) | Median 37, IQR 15–75 | |
| PSA at PET/CT (ng/ml) | < 0.2 | 45 (15.2%) |
| 0.2–0.5 | 148 (49.8%) | |
| > 0.5–1.0 | 41 (13.8%) | |
| > 1.0 | 63 (21.2%) |
IQR interquartile range; ISUP international society of urological pathology; LN lymph node; PSA prostate-specific antigen; and RP radical prostatectomy